Active Ingredient History
Methylphenidate is a CNS stimulant approved for the treatment of narcolepsy and attention deficit hyperactivity disorder. The drug is believed to bind the dopamine transporter in the presynaptic cell membrane, thereby blocking the reuptake of dopamine and causing an increase in extracellular dopamine levels. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Narcolepsy (approved 1955)
Accidental Falls (Phase 4)
Agoraphobia (Phase 4)
AIDS Dementia Complex (Phase 3)
Alcoholism (Phase 4)
Alzheimer Disease (Phase 4)
Anemia, Sickle Cell (Phase 3)
Anesthesia (Phase 1/Phase 2)
Anesthesia, General (Phase 1/Phase 2)
Anxiety Disorders (Phase 4)
Apathy (Phase 4)
Asthenia (Phase 3)
Autism Spectrum Disorder (Phase 4)
Autistic Disorder (Phase 4)
Behavior, Addictive (Phase 1/Phase 2)
Binge-Eating Disorder (Phase 2)
Bipolar Disorder (Phase 4)
Brain Injuries (Phase 4)
Brain Injuries, Traumatic (Phase 4)
Brain Neoplasms (Phase 4)
Breast Neoplasms (Phase 3)
Carboxylesterase (Phase 4)
Central Nervous System Stimulants (Phase 4)
Child, Preschool (Phase 4)
Cocaine-Related Disorders (Phase 4)
Cognition (Phase 4)
Cognition Disorders (Phase 4)
Cognitive Dysfunction (Phase 4)
Coma (Phase 1)
Conduct Disorder (Phase 4)
Consciousness Disorders (Phase 1)
Deficiency Diseases (Phase 4)
Delayed Emergence from Anesthesia (Phase 1)
Delirium (Phase 3)
Dementia (Phase 4)
Dementia, Vascular (Phase 2/Phase 3)
Depression (Phase 4)
Depressive Disorder, Major (Phase 3)
Diabetes Mellitus (Phase 4)
DiGeorge Syndrome (Phase 4)
Down Syndrome (Phase 1/Phase 2)
Drug Interactions (Phase 4)
Epilepsy (Phase 4)
Esterases (Phase 4)
Executive Function (Phase 4)
Exercise Test (Phase 4)
Fatigue (Phase 3)
Fetal Alcohol Spectrum Disorders (Phase 4)
Fragile X Syndrome (Phase 4)
Gait (Phase 4)
Gait Disorders, Neurologic (Phase 4)
Gastrointestinal Neoplasms (Phase 3)
Growth (Phase 4)
Healthy Volunteers (Phase 4)
Hoarding Disorder (Phase 2)
Hypotension, Orthostatic (Phase 1)
Hypothermia (Phase 4)
Impulsive Behavior (Early Phase 1)
Lymphoma (Phase 2)
Mania (Phase 3)
Methamphetamine (Phase 2)
Mood Disorders (Phase 2)
Motivation (Early Phase 1)
Multiple Sclerosis (Phase 3)
Multiple Sclerosis, Chronic Progressive (Phase 1)
Multiple Sclerosis, Relapsing-Remitting (Phase 1)
Myotonic Dystrophy (Phase 2/Phase 3)
Naltrexone (Phase 1)
Neoplasm Metastasis (Phase 3)
Neoplasms (Phase 3)
Neurodevelopmental Disorders (Phase 4)
Neurofibromatosis 1 (Phase 4)
Obesity (Phase 3)
Obsessive-Compulsive Disorder (Phase 4)
Opioid-Related Disorders (Phase 2/Phase 3)
Panic Disorder (Phase 4)
Parkinson Disease (Phase 4)
Pharmacokinetics (Phase 1)
Pharmacology (Phase 2)
Phobia, Social (Phase 4)
Physiology (Phase 1)
Prostatic Neoplasms (Phase 2)
Psilocybin (Early Phase 1)
Psychological Distress (Phase 1)
Pure Autonomic Failure (Phase 1)
Quality of Life (Phase 3)
Reading (Phase 4)
Sleep Disorders, Intrinsic (Phase 4)
Sleep Wake Disorders (Phase 2)
Smoking (Phase 3)
Social Cognition (Early Phase 1)
Stress Disorders, Post-Traumatic (Phase 2)
Stroke (Phase 4)
Substance Abuse, Oral (Phase 1/Phase 2)
Substance-Related Disorders (Phase 4)
Tobacco Use Disorder (Phase 1)
Trichotillomania (Phase 4)
Williams Syndrome (Phase 4)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
